文献速递精神分裂症与精神病性障碍心境障碍

2000至2019年英国初级保健中严重精神障碍患者抗精神病药处方:20年谁接受治疗、用何种药物及剂量的调查

Prescribing of antipsychotics for people diagnosed with severe mental illness in UK primary care 2000-2019: 20-year investigation of who receives treatment, with which agents and at what doses.
PubMed 文献 · Br J Psychiatry · 2024-12-19

基于英国临床实践研究数据链的队列研究,纳入2000至2017年初级保健首诊严重精神障碍患者309378例,其中212618例(68.7%)在2000至2019年间被处方抗精神病药。奥氮平、喹硫平、利培酮和阿立哌唑占全部抗精神病药处方的78.8%;精神分裂症患者处方比例(81.0%)高于双相障碍(64.6%)和其他非器质性精神病(65.7%)。作者认为需进一步研究以理解为何某些群体被处方更高剂量及更可能接受长效注射抗精神病药。

要点

  • 2000至2019年间68.7%的严重精神障碍患者被处方抗精神病药,精神分裂症患者处方比例最高(81.0%)。
  • 奥氮平、喹硫平、利培酮和阿立哌唑占全部抗精神病药处方的78.8%。
  • 精神分裂症诊断、少数族裔、男性、较年轻和相对剥夺程度更高者被处方更高的奥氮平等效日剂量。

核心结论

  • 抗精神病药处方以奥氮平、喹硫平、利培酮和阿立哌唑为主,且不同亚组在是否接受抗精神病药及处方剂量上存在潜在差异。
  • 作者认为需进一步研究以理解为何某些群体被处方更高剂量及更可能接受长效注射抗精神病药,从而为优化处方和确保公平照护提供信息。

研究设计与样本

  • 基于英国临床实践研究数据链的队列研究,纳入2000至2017年初级保健首诊严重精神障碍(精神分裂症、双相障碍、其他非器质性精神病)患者309378例。
  • 暴露定义为2000至2019年间在初级保健中至少被处方一种抗精神病药;比较处方与未处方患者特征,计算年度处方患病率,并按患者特征分层计算平均日剂量。

主要发现

  • 309378例首诊严重精神障碍患者中,212618例(68.7%)在2000至2019年间被处方抗精神病药。
  • 抗精神病药处方患病率2000年为每1000例患者426例(95%CI 420-433),2016年达峰值550例(95%CI 547-553),2019年降至470例(95%CI 468-473)。
  • 被处方抗精神病药的比例:精神分裂症患者81.0%,高于双相障碍患者64.6%和其他非器质性精神病患者65.7%。
  • 奥氮平、喹硫平、利培酮和阿立哌唑占全部抗精神病药处方的78.8%。
  • 精神分裂症诊断、少数族裔、男性、较年轻和相对剥夺程度更高的患者被处方更高的平均奥氮平等效总日剂量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Contemporary data relating to antipsychotic prescribing in UK primary care for patients diagnosed with severe mental illness (SMI) are lacking. AIMS: To describe contemporary patterns of antipsychotic prescribing in UK primary care for patients diagnosed with SMI. METHOD: Cohort study of patients with an SMI diagnosis (i.e. schizophrenia, bipolar disorder, other non-organic psychoses) first recorded in primary care between 2000 and 2017 derived from Clinical Practice Research Datalink. Patients were considered exposed to antipsychotics if prescribed at least one antipsychotic in primary care between 2000 and 2019. We compared characteristics of patients prescribed and not prescribed antipsychotics; calculated annual prevalence rates for antipsychotic prescribing; and computed average daily antipsychotic doses stratified by patient characteristics. RESULTS: Of 309 378 patients first diagnosed with an SMI in primary care between 2000 and 2017, 212,618 (68.7%) were prescribed an antipsychotic between 2000 and 2019. Antipsychotic prescribing prevalence was 426 (95% CI, 420-433) per 1000 patients in the year 2000, reaching a peak of 550 (547-553) in 2016, decreasing to 470 (468-473) in 2019. The proportion prescribed antipsychotics was higher among patients diagnosed with schizophrenia (81.0%) than with bipolar disorder (64.6%) and other non-organic psychoses (65.7%). Olanzapine, quetiapine, risperidone and aripiprazole accounted for 78.8% of all antipsychotic prescriptions. Higher mean olanzapine equivalent total daily doses were prescribed to patients with the following characteristics: schizophrenia diagnosis, ethnic minority status, male gender, younger age and greater relative deprivation. CONCLUSIONS: Antipsychotic prescribing is dominated by olanzapine, quetiapine, risperidone and aripiprazole. We identified potential disparities in both the receipt and prescribed doses of antipsychotics across subgroups. To inform efforts to optimise prescribing and ensure equity of care, further research is needed to understand why certain groups are prescribed higher doses and are more likely to be treated with long-acting injectable antipsychotics compared with others.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Richards-Belle A, Launders N, Hardoon S, et al. Prescribing of antipsychotics for people diagnosed with severe mental illness in UK primary care 2000-2019: 20-year investigation of who receives treatment, with which agents and at what doses. Br J Psychiatry. 2024. PMID: 39690823. doi:10.1192/bjp.2024.186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。